ID   ACSuR
AC   CVCL_XI64
DR   cancercelllines; CVCL_XI64
DR   CCRID; 4201PAT-CCTCC00548
DR   CCRID; 4201PAT-CCTCC00565
DR   Wikidata; Q93313455
RX   Patent=CN104988122B;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014238.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:38940; Sunitinib.
CC   Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (from parent cell line).
CC   Misspelling: ACSu; CCRID=4201PAT-CCTCC00548.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C6975; Papillary renal cell carcinoma
DI   ORDO; Orphanet_319298; Papillary renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1067 ! ACHN
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 8
//
RX   Patent=CN104988122B;
RA   Qu L., Wang L.-H., Liu B., Chen C., Wu Z.-J., Zhang W.;
RT   "Renal cancer sunitinib drug-resistant cell system and establishment
RT   method thereof.";
RL   Patent number CN104988122B, 21-Sep-2018.
//